MLV Capital Starts Coverage on ACRX - $13 Price Target
MLV Capital initiated coverage on shares of AcelRx Pharmaceuticals (NASDAQ: ACRX) in a research note issued on Monday. The firm set a “buy” rating and a $13.00 price target on the stock.
ACRX has been the subject of a number of other recent research reports. Analysts at Mizuho initiated coverage on shares of AcelRx Pharmaceuticals in a research note to investors on Wednesday, January 30th. They set a “buy” rating and a $13.00 price target on the stock. Analysts at Cowen reiterated an “outperform” rating on shares of AcelRx Pharmaceuticals in a research note to investors on Thursday, November 15th.
Zacks has a buy rating of 2. We need some publicity. Do any of you know another MB thats so quiet. Heck even some of the most worthless stocks have more activity. Lets spresd the word but it looks like a noce base is being formed.
I know right? Just be patient...Any significant amount of buying shoots this stock up...I can literally move the market on this stock with a 1000 share purchase or sell,There is a low flowat out there with minimal retail ownership. Once the data comes out again, assuming if positive, this thing will move pretty firece...Opposite side of the coin, any selling colume will send it in a spiral.